PUBLICATIONS

PPM1D modulates hematopoietic cell fitness and response to DNA damage and is a therapeutic target in myeloid malignance

Blood

Miller PG, Sperling AS, Mayerhofer C, McConkey M, Ellegast JM, Silva CD, Cohen DN, Wang C, Sharda A, Yan N, Saha S, Schluter C, Schechter IA, Słabicki M, Sandoval B, Kahn J, Boettcher S, Gibson CJ, Scadden DT, Stegmaier K, Bhatt S, Lindsley RC, Ebert BL.

2023 Aug 18

BH3 profiling identifies BCL-2 dependence in adult patients with early T-cell progenitor acute lymphoblastic leukemia

Blood Advances

Olesinski EA, Bhatia KS, Mahesh AN, Rosli S, Mohamed JS, Jen WY, Jain N, Garcia JS, Wong GC, Ooi M, Letai A, Konopleva M, Bhatt S.

2023 Jun 27;7(12):2917-2923.

Apoptosis, necrosis, and other forms of cell death

Reference Module in Biomedical Sciences

Mahesh AN, Lim NSE, Wong MH, Ray SD, Bhatt S.

2023 Jun 23

Cytochrome P450

Reference Module in Biomedical Sciences

Bhatia KS, Mahesh AN, Bhatt S.

2023 Mar 8

Cell Cycle

Reference Module in Biomedical Sciences

Mahesh AN, Bhatia KS, Bhatt S.

2023 Jan 4

CALR-mutated cells are vulnerable to combined inhibition of the proteasome and the endoplasmic reticulum stress response

Leukemia

Jutzi JS, Marneth AE, Jiménez-Santos MJ, Hem J, Guerra-Moreno A, Rolles B, Bhatt S, Myers SA, Carr SA, Hong Y, Pozdnyakova O, van Galen P, Al-Shahrour F, Nam AS, Mullally A.

2022 Dec;37(2):359-369.

Combination therapy targeting Erk1/2 and CDK4/6i in relapsed refractory multiple myeloma.

Leukemia

Adamia S, Bhatt S, Wen K, Chyra Z, Fell GG, Tai YT, Pioso MS, Abiatari I, Letai A, Dorfman DM, Hideshima T, Anderson KC.
2022 Apr;36(4):1088-1101

Identification of Novel Targets Based on Splicing Alterations for Undruggable RAS/CDK Signaling Cascade in Multiple Myeloma,

Blood

Adamia S, Chyra Z, O'Keefe M, Bhatt S, Wen K, Fell G, Tai YT, Letai A, Abiatari I, Dorfman D, Hideshima T, Anderson K.

2021 November;138, Supplement 1, 2021, Page 2688.

Dynamic BH3 profiling method for rapid identification of active therapy in BH3 mimetics resistant xenograft mouse model

Star Protocols

Olesinski EA, Bhatt S.

2021 May 12;2(2):100461

Suramin, penciclovir, and anidulafungin exhibit potential in the treatment of COVID-19 via binding to nsp12 of SARS-CoV-

Journal of Biomolecular Structure and Dynamics

Dey SK, Saini M, Dhembla C, Bhatt S, Rajesh AS, Anand V, Das HK, Kundu S

2022;40(24):14067-14083

Reduced Mitochondrial Apoptotic Priming Drives Resistance to BH3 Mimetics in Acute Myeloid Leukemia.

Cancer Cell

Bhatt S, Pioso MS, Olesinski EA, Yilma B, Ryan JA, Mashaka T, Leutz B, Adamia S, Zhu H, Kuang Y, Mogili A, Louissaint AJ, Bohl SR, Kim AS, Mehta AK, Sanghavi S, Wang Y, Morris E, Halilovic E, Paweletz CP, Weinstock DM, Garcia JS, Letai A.

2020 Dec 14;38(6):872-890.e6

Increased mitochondrial apoptotic priming with targeted therapy predicts clinical response to re-induction chemotherapy.

American Journal of Hematology

Garcia JS*, Bhatt S*, Fell G, Sperling AS, Burgess M, Keshishian H, Yilma B, Brunner A, Neuberg D, Carr SA, Ebert BL, Ballen K, Stone RM, DeAngelo DJ, Medeiros BC, Letai A.

2020 Mar;95(3):245-250.

Patterns of substrate affinity, competition, and degradation kinetics underlie biological activity of thalidomide analogs.

Blood

Sperling AS, Burgess M, Keshishian H, Gasser JA, Bhatt S, Jan M, Słabicki M, Sellar RS, Fink EC, Miller PG, Liddicoat BJ, Sievers QL, Sharma R, Adams DN, Olesinski EA, Fulciniti M, Udeshi ND, Kuhn E, Letai A, Munshi NC, Carr SA, Ebert BL.

2019 Jul 11;134(2):160-170.

Statins enhance efficacy of venetoclax in blood cancers.

Science Translational Medicine

Lee JS, Roberts A, Juarez D, Vo TT, Bhatt S, Herzog LO, Mallya S, Bellin RJ, Agarwal SK, Salem AH, Xu T, Jia J, Li L, Hanna JR, Davids MS, Fleischman AG, O'Brien S, Lam LT, Leverson JD, Letai A, Schatz JH, Fruman DA.

2018 Jun 13;10(445).

PPM1D modulates hematopoietic cell fitness and response to DNA damage and is a therapeutic target in myeloid malignancy.

Blood (In press)

Miller PG, Sperling AS, Mayerhoffer C, McConkey ME, Elegast J, Silva CD, Wang C, Cohen DN, Sharda A, Yan N, Saha S, Schluter C, Schechter I, Słabicki M, Sandoval B, Kahn J, Boettcher S, Gibson CJ, Scadden DT, Stegmaeir K, Bhatt S, Lindsley RC, Ebert BL.

Inhibition of USP10 induces degradation of oncogenic FLT3.

Nature Chemical Biology

Weisberg EL, Schauer NJ, Yang J, Lamberto I, Doherty L, Bhatt S, Nonami A, Meng C, Letai A, Wright R, Tiv H, Gokhale PC, Ritorto MS, De Cesare V, Trost M, Christodoulou A, Christie A, Weinstock DM, Adamia S, Stone R, Chauhan D, Anderson KC, Seo HS, Dhe-Paganon S, Sattler M, Gray NS, Griffin JD, Buhrlage SJ.

2017 Dec;13(12):1207-1215.

Anti-CD20-interleukin-21 fusokine targets malignant B cells via direct apoptosis and NK-cell-dependent cytotoxicity.

Blood.

Bhatt S*, Parvin S*, Zhang Y, Cho HM, Kunkalla K, Vega F, Timmerman JM, Shin SU, Rosenblatt JD, Lossos IS.

2017 Apr 20;129(16):2246-2256.

Interleukin 21 - its potential role in the therapy of B-cell lymphomas.

Leukemia & Lymphoma

Bhatt S, Sarosiek KA, Lossos IS.

2017 Jan;58(1):17-29.

Pathophysiological significance and therapeutic targeting of germinal center kinase in diffuse large B-cell lymphoma.

Blood

Matthews JM, Bhatt S, Patricelli MP, Nomanbhoy TK, Jiang X, Natkunam Y, Gentles AJ, Martinez E, Zhu D, Chapman JR, Cortizas E, Shyam R, Chinichian S, Advani R, Tan L, Zhang J, Choi HG, Tibshirani R, Buhrlage SJ, Gratzinger D, Verdun R, Gray NS, Lossos IS.

2016 Jul 14;128(2):239-48.

miR-181a negatively regulates NF-κB signaling and affects activated B-cell-like diffuse large B-cell lymphoma pathogenesis.

Blood

Kozloski GA, Jiang X, Bhatt S, Ruiz J, Vega F, Shaknovich R, Melnick A, Lossos IS.

2016 Jun 9;127(23):2856-66.

Direct and immune-mediated cytotoxicity of interleukin-21 contributes to antitumor effects in mantle cell lymphoma.

Blood

Bhatt S, Matthews J, Parvin S, Sarosiek KA, Zhao D, Jiang X, Isik E, Letai A, Lossos IS.

2015 Sep 24;126(13):1555-64.

Chlamydophila psittaci-negative ocular adnexal marginal zone lymphomas express self polyreactive B-cell receptors.

Leukemia

Zhu D*, Bhatt S*, Lu X, Guo F, Veelken H, Hsu DK, Liu FT, Alvarez Cubela S, Kunkalla K, Vega F, Chapman-Fredricks JR, Lossos IS.

2015 Jul;29(7):1587-99.

CD30 targeting with brentuximab vedotin: a novel therapeutic approach to primary effusion lymphoma.

Blood

Bhatt S, Ashlock BM, Natkunam Y, Sujoy V, Chapman JR, Ramos JC, Mesri EA, Lossos IS.

2013 Aug 15;122(7):1233-42.

Efficacious proteasome/HDAC inhibitor combination therapy for primary effusion lymphoma.

Journal of Clinical Investigation

Bhatt S, Ashlock BM, Toomey NL, Diaz LA, Mesri EA, Lossos IS, Ramos JC.

2013 Jun;123(6):2616-28.

Efficacy of bortezomib in a direct xenograft model of primary effusion lymphoma.

Proceedings of the National Academy of Sciences of the United States of America

Sarosiek KA, Cavallin LE, Bhatt S, Toomey NL, Natkunam Y, Blasini W, Gentles AJ, Ramos JC, Mesri EA, Lossos IS.

2010 Jul 20;107(29):13069-74.